Antibody neutralisation of emerging SARS-CoV-2 subvariants: EG.5.1 and XBC.1.6
- PMID: 37708906
- DOI: 10.1016/S1473-3099(23)00555-8
Antibody neutralisation of emerging SARS-CoV-2 subvariants: EG.5.1 and XBC.1.6
Erratum in
-
Correction to Lancet Infect Dis 2023; 23: e397-98.Lancet Infect Dis. 2023 Nov;23(11):e467. doi: 10.1016/S1473-3099(23)00591-1. Epub 2023 Sep 18. Lancet Infect Dis. 2023. PMID: 37734393 No abstract available.
Conflict of interest statement
QW, YG, RMZ, and JH contributed equally. LL and DDH contributed equally. AG served on a scientific advisory board for Janssen Pharmaceuticals. DDH is a Co-founder of TaiMed Biologics and RenBio, Consultant to WuXi Biologics and Brii Biosciences, and Board Director for Vicarious Surgical. All other authors declare no competing interests.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
